AAPL343.17-4.56 (-1.31%) ▼|ABBV288.70+3.10 (+1.08%) ▲|ABT104.34+0.64 (+0.62%) ▲|ACN250.68+1.31 (+0.52%) ▲|ADBE261.87-1.96 (-0.74%) ▼|AMAT382.31+5.07 (+1.34%) ▲|AMD518.10+1.31 (+0.25%) ▲|AMGN449.29+10.03 (+2.28%) ▲|AMT190.50+1.53 (+0.81%) ▲|AMZN250.30+2.30 (+0.93%) ▲|AVGO326.13+4.45 (+1.38%) ▲|AXP317.16+3.94 (+1.26%) ▲|BA187.98-0.37 (-0.19%) ▼|BAC51.24+0.68 (+1.34%) ▲|BKNG154.60-1.23 (-0.79%) ▼|BLK1,133.45+15.20 (+1.36%) ▲|BMY61.69+0.21 (+0.34%) ▲|BNY147.92+3.28 (+2.26%) ▲|BRK-B545.14+2.95 (+0.54%) ▲|C122.56+1.94 (+1.61%) ▲|CAT685.18-0.19 (-0.03%) ▼|CL94.03-0.02 (-0.02%) ▼|CMCSA22.44-0.26 (-1.12%) ▼|COF204.39+3.05 (+1.51%) ▲|COP150.40-0.41 (-0.27%) ▼|COST1,014.90+11.58 (+1.15%) ▲|CRM248.19-0.39 (-0.15%) ▼|CSCO108.72+2.22 (+2.08%) ▲|CVS94.48+1.01 (+1.08%) ▲|CVX232.24-0.97 (-0.42%) ▼|DE631.72-14.43 (-2.23%) ▼|DHR232.83+2.33 (+1.01%) ▲|DIS112.06-0.46 (-0.41%) ▼|DUK125.19+0.21 (+0.17%) ▲|EMR162.17+0.58 (+0.36%) ▲|FDX303.68+4.96 (+1.66%) ▲|GD355.16+5.80 (+1.66%) ▲|GE288.64+3.00 (+1.05%) ▲|GEV830.21+15.21 (+1.87%) ▲|GILD159.23+3.19 (+2.04%) ▲|GM76.75+0.83 (+1.09%) ▲|GOOG317.09-0.19 (-0.06%) ▼|GOOGL320.15-0.06 (-0.02%) ▼|GS893.84+18.16 (+2.07%) ▲|HD321.62+1.79 (+0.56%) ▲|HON220.34-0.81 (-0.36%) ▼|IBM255.54+1.98 (+0.78%) ▲|INTC87.42+0.46 (+0.53%) ▲|INTU342.94-0.45 (-0.13%) ▼|ISRG458.00+5.71 (+1.26%) ▲|JNJ270.14+6.33 (+2.40%) ▲|JPM336.17+4.59 (+1.38%) ▲|KO92.20-0.51 (-0.55%) ▼|LIN510.11+1.28 (+0.25%) ▲|LLY1,284.44+10.98 (+0.86%) ▲|LMT621.74+17.56 (+2.91%) ▲|LOW200.44+1.76 (+0.88%) ▲|LRCX236.13+6.03 (+2.62%) ▲|MA618.17-5.43 (-0.87%) ▼|MCD252.42+3.96 (+1.59%) ▲|MDLZ63.23-0.58 (-0.90%) ▼|MDT95.57+0.16 (+0.17%) ▲|META636.28-6.34 (-0.99%) ▼|MMM174.40+0.94 (+0.54%) ▲|MO73.81-0.50 (-0.67%) ▼|MRK144.38-0.89 (-0.61%) ▼|MS184.10+4.61 (+2.57%) ▲|MSFT526.66+2.15 (+0.41%) ▲|MU888.06+10.51 (+1.20%) ▲|NEE82.68+0.58 (+0.70%) ▲|NFLX65.29-0.57 (-0.86%) ▼|NKE38.28+0.98 (+2.61%) ▲|NOW157.54-1.42 (-0.89%) ▼|NVDA214.72+3.76 (+1.78%) ▲|ORCL126.40+0.24 (+0.19%) ▲|PEP137.09+1.32 (+0.97%) ▲|PFE30.12+0.09 (+0.28%) ▲|PG160.93-0.09 (-0.06%) ▼|PLTR195.94-0.82 (-0.41%) ▼|PM202.91+3.44 (+1.72%) ▲|QCOM176.91+1.00 (+0.57%) ▲|RTX194.88+3.87 (+2.03%) ▲|SBUX103.05+2.25 (+2.23%) ▲|SCHW90.79+0.21 (+0.23%) ▲|SO92.81-0.08 (-0.09%) ▼|SPG213.24+1.61 (+0.76%) ▲|T21.06+0.13 (+0.60%) ▲|TMO681.35+7.53 (+1.12%) ▲|TMUS144.85-1.69 (-1.15%) ▼|TSLA393.83+21.61 (+5.80%) ▲|TXN285.58+0.89 (+0.31%) ▲|UBER66.80+0.10 (+0.15%) ▲|UNH419.82+1.73 (+0.41%) ▲|UNP294.92+2.05 (+0.70%) ▲|UPS101.05-0.01 (-0.01%) ▼|USB60.20+0.62 (+1.04%) ▲|V405.73-2.19 (-0.54%) ▼|VZ43.53-1.14 (-2.54%) ▼|WFC83.75+1.36 (+1.64%) ▲|WMT121.48+1.59 (+1.33%) ▲|XOM182.82-0.39 (-0.21%) ▼|AAPL343.17-4.56 (-1.31%) ▼|ABBV288.70+3.10 (+1.08%) ▲|ABT104.34+0.64 (+0.62%) ▲|ACN250.68+1.31 (+0.52%) ▲|ADBE261.87-1.96 (-0.74%) ▼|AMAT382.31+5.07 (+1.34%) ▲|AMD518.10+1.31 (+0.25%) ▲|AMGN449.29+10.03 (+2.28%) ▲|AMT190.50+1.53 (+0.81%) ▲|AMZN250.30+2.30 (+0.93%) ▲|AVGO326.13+4.45 (+1.38%) ▲|AXP317.16+3.94 (+1.26%) ▲|BA187.98-0.37 (-0.19%) ▼|BAC51.24+0.68 (+1.34%) ▲|BKNG154.60-1.23 (-0.79%) ▼|BLK1,133.45+15.20 (+1.36%) ▲|BMY61.69+0.21 (+0.34%) ▲|BNY147.92+3.28 (+2.26%) ▲|BRK-B545.14+2.95 (+0.54%) ▲|C122.56+1.94 (+1.61%) ▲|CAT685.18-0.19 (-0.03%) ▼|CL94.03-0.02 (-0.02%) ▼|CMCSA22.44-0.26 (-1.12%) ▼|COF204.39+3.05 (+1.51%) ▲|COP150.40-0.41 (-0.27%) ▼|COST1,014.90+11.58 (+1.15%) ▲|CRM248.19-0.39 (-0.15%) ▼|CSCO108.72+2.22 (+2.08%) ▲|CVS94.48+1.01 (+1.08%) ▲|CVX232.24-0.97 (-0.42%) ▼|DE631.72-14.43 (-2.23%) ▼|DHR232.83+2.33 (+1.01%) ▲|DIS112.06-0.46 (-0.41%) ▼|DUK125.19+0.21 (+0.17%) ▲|EMR162.17+0.58 (+0.36%) ▲|FDX303.68+4.96 (+1.66%) ▲|GD355.16+5.80 (+1.66%) ▲|GE288.64+3.00 (+1.05%) ▲|GEV830.21+15.21 (+1.87%) ▲|GILD159.23+3.19 (+2.04%) ▲|GM76.75+0.83 (+1.09%) ▲|GOOG317.09-0.19 (-0.06%) ▼|GOOGL320.15-0.06 (-0.02%) ▼|GS893.84+18.16 (+2.07%) ▲|HD321.62+1.79 (+0.56%) ▲|HON220.34-0.81 (-0.36%) ▼|IBM255.54+1.98 (+0.78%) ▲|INTC87.42+0.46 (+0.53%) ▲|INTU342.94-0.45 (-0.13%) ▼|ISRG458.00+5.71 (+1.26%) ▲|JNJ270.14+6.33 (+2.40%) ▲|JPM336.17+4.59 (+1.38%) ▲|KO92.20-0.51 (-0.55%) ▼|LIN510.11+1.28 (+0.25%) ▲|LLY1,284.44+10.98 (+0.86%) ▲|LMT621.74+17.56 (+2.91%) ▲|LOW200.44+1.76 (+0.88%) ▲|LRCX236.13+6.03 (+2.62%) ▲|MA618.17-5.43 (-0.87%) ▼|MCD252.42+3.96 (+1.59%) ▲|MDLZ63.23-0.58 (-0.90%) ▼|MDT95.57+0.16 (+0.17%) ▲|META636.28-6.34 (-0.99%) ▼|MMM174.40+0.94 (+0.54%) ▲|MO73.81-0.50 (-0.67%) ▼|MRK144.38-0.89 (-0.61%) ▼|MS184.10+4.61 (+2.57%) ▲|MSFT526.66+2.15 (+0.41%) ▲|MU888.06+10.51 (+1.20%) ▲|NEE82.68+0.58 (+0.70%) ▲|NFLX65.29-0.57 (-0.86%) ▼|NKE38.28+0.98 (+2.61%) ▲|NOW157.54-1.42 (-0.89%) ▼|NVDA214.72+3.76 (+1.78%) ▲|ORCL126.40+0.24 (+0.19%) ▲|PEP137.09+1.32 (+0.97%) ▲|PFE30.12+0.09 (+0.28%) ▲|PG160.93-0.09 (-0.06%) ▼|PLTR195.94-0.82 (-0.41%) ▼|PM202.91+3.44 (+1.72%) ▲|QCOM176.91+1.00 (+0.57%) ▲|RTX194.88+3.87 (+2.03%) ▲|SBUX103.05+2.25 (+2.23%) ▲|SCHW90.79+0.21 (+0.23%) ▲|SO92.81-0.08 (-0.09%) ▼|SPG213.24+1.61 (+0.76%) ▲|T21.06+0.13 (+0.60%) ▲|TMO681.35+7.53 (+1.12%) ▲|TMUS144.85-1.69 (-1.15%) ▼|TSLA393.83+21.61 (+5.80%) ▲|TXN285.58+0.89 (+0.31%) ▲|UBER66.80+0.10 (+0.15%) ▲|UNH419.82+1.73 (+0.41%) ▲|UNP294.92+2.05 (+0.70%) ▲|UPS101.05-0.01 (-0.01%) ▼|USB60.20+0.62 (+1.04%) ▲|V405.73-2.19 (-0.54%) ▼|VZ43.53-1.14 (-2.54%) ▼|WFC83.75+1.36 (+1.64%) ▲|WMT121.48+1.59 (+1.33%) ▲|XOM182.82-0.39 (-0.21%) ▼|
11 C
New York
Monday, October 26, 2026

Tag: TDS TRI

newsFORsourcecompanycontentinformation1releasesmarket

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research,...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

Median DOR of 44.3 months supports durability of response4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survivalLong-term...

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ --  ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for...

Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026

STOCKHOLM, Oct. 19, 2026 /PRNewswire/ -- Sobi® today announced that seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical...

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Late-Breaking Clinical Trial Results Announced at VIVA 2026

LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTDS TRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers